NCT06268067 is a clinical trial of PET/CT in Renal Uptake at F-18-FDG PET/CT, sponsored by Assiut University.

Who is sponsoring NCT06268067?

NCT06268067 is sponsored by Assiut University.

What drugs are being tested in NCT06268067?

Interventions in NCT06268067: PET/CT.

What condition does NCT06268067 study?

NCT06268067 studies Renal Uptake at F-18-FDG PET/CT.

Is NCT06268067 still recruiting?

NCT06268067 is currently status unknown. Last updated 20 February 2024.

Last reviewed 2024-02-20 · How we verify

NCT06268067

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kidney Uptake at F-18 FDG PET/CT Studies and Renal Function Status

Status unknown Last updated 20 February 2024

What this trial tests

trial testing PET/CT in Renal Uptake at F-18-FDG PET/CT in 97 participants. Status unknown.

Timeline

1 March 2024

Primary endpoint
1 March 2025

1 April 2025

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	97
Start date	1 March 2024
Primary completion	1 March 2025
Estimated completion	1 April 2025

Drugs / interventions tested

PET/CT

Conditions studied

Renal Uptake at F-18-FDG PET/CT — all drugs for Renal Uptake at F-18-FDG PET/CT →

Sponsor

Assiut University

Who can join

Adults 19 to 75, any sex, with Renal Uptake at F-18-FDG PET/CT. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Searching for a possible correlation between renal uptake at F-18-FDG PET/CT and renal functional parameters in both normal subjects and patients with CKD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PET/CT

Trials testing the same drug.

NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07523997 — Imaging of Endometriosis With Total-body PET-CT (PET-Endo) · not yet recruiting
NCT06914427 — PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique · NA · not yet recruiting
NCT06636175 — 64Cu-LLP2A for Imaging Hematologic Malignancies · EARLY_PHASE1 · recruiting
NCT06479187 — PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer · Phase 4 · active not recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06268067 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 20 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06268067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing